Skip to content

Study · Not a test of the peptide alone · 2022

2 results

A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.

Romera I, Artime E, Ihle K, Díaz-Cerezo S, Rubio de-Santos M, de Prado A, Cebrián-Cuenca A, Conget I

Advances in therapy11 Jun 2022Cited by 8 (Europe PMC)

PMID35689162 (opens in a new tab)DOI10.1007/s12325-022-02196-0 (opens in a new tab)PepBankPUB-35689162
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneObservational studyOther

    In a Spanish cohort of adults with type 2 diabetes, 10.1% met the key selection criteria of the LEADER trial of liraglutide.

    In plain wordsIn Spanish adults with type 2 diabetes, 10.1% would have qualified for the liraglutide LEADER trial.

    Peptide
    Liraglutide
    Outcome
    Not applicableProportion of Spanish T2D cohort meeting LEADER selection criteria
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Metabolic and weight

    Measurements

    Proportion meeting selection criteria
    10.1%
    LEADER

    Source sentences

    Summary
    The proportions of subjects in the Spanish cohort who met the CVOTs key selection criteria were 10.1% for LEADER, 53.6% for REWIND, and 10.4% for SUSTAIN-6.
    1 context sentence
    Summary · context
    The REPRESENT study aims to examine whether participants enrolled in glucagon-like peptide 1 receptor agonist cardiovascular outcome trials (CVOTs) LEADER (liraglutide), REWIND (dulaglutide), and SUSTAIN-6 (injectable semaglutide) are representative of the Spanish population with type 2 diabetes (T2D).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studyOther

    In a Spanish cohort of adults with type 2 diabetes, 10.4% met the key selection criteria of the SUSTAIN-6 trial of injectable semaglutide.

    In plain wordsIn Spanish adults with type 2 diabetes, 10.4% would have qualified for the semaglutide SUSTAIN-6 trial.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion of Spanish T2D cohort meeting SUSTAIN-6 selection criteria
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Metabolic and weight

    Measurements

    Proportion meeting selection criteria
    10.4%
    SUSTAIN-6

    Source sentences

    Summary
    The proportions of subjects in the Spanish cohort who met the CVOTs key selection criteria were 10.1% for LEADER, 53.6% for REWIND, and 10.4% for SUSTAIN-6.
    1 context sentence
    Summary · context
    The REPRESENT study aims to examine whether participants enrolled in glucagon-like peptide 1 receptor agonist cardiovascular outcome trials (CVOTs) LEADER (liraglutide), REWIND (dulaglutide), and SUSTAIN-6 (injectable semaglutide) are representative of the Spanish population with type 2 diabetes (T2D).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.